Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06557954
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-14
Brief Title:
Cervical Cytology DNA Methylation for Cervical Cancer Screening
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Cervical Cytology DNA Methylation for Cervical Cancer Screening A Real Word Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Cervical cancer represents one of the foremost causes of cancer-related morbidity and mortality among women worldwide Given the current limitations such as the low specificity of human papillomavirus HPV testing and the relatively low sensitivity of cytological examinations there is a pressing need for a novel non-invasive safe and precise screening method This study aims to undertake a multicentre real-world investigation incorporating at least 10 sub-centres and enrolling 30000 participants Histopathological examination results will serve as the gold standard for evaluating the screening efficacy of human PAX1 and JAM3 gene methylation assays PAX1mJAM3m HPV testing and cytological examinations Furthermore the study seeks to elucidate the relationship between DNA methylation levels and persistent HPV infection while also assessing the applicability of PAX1mJAM3m across diverse clinical settings By focusing on alterations in DNA methylation levels within cervical exfoliated cells as the primary research trajectory this study aspires to furnish novel insights and theoretical foundations for the prevention and management of cervical cancer targeting PAX1mJAM3m The ultimate objective is to facilitate the clinical implementation of an enhanced cervical cancer screening protocol thereby addressing the deficiencies of current screening methodologies achieving greater precision in cervical cancer screening and effectively reducing the incidence of cervical cancer while mitigating the risks of overdiagnosis and overtreatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None